Analyst Price Target is $9.00
▲ +598.00% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Panbela Therapeutics in the last 3 months. The average price target is $9.00, with a high forecast of $13.00 and a low forecast of $5.00. The average price target represents a 598.00% upside from the last price of $1.29.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Panbela Therapeutics.
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, together with its subsidiaries, focuses on developing disruptive therapeutics for the treatment of patients with cancer. The company focuses on diseases of the pancreas, including pancreatitis and pancreatic cancer, as well as neoadjuvant pancreatic cancer, colorectal cancer, ovarian cancer, and other agents in other cancer indications. Its lead product candidate is SBP-101, which is in Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma. The company was formerly known as Sun BioPharma, Inc. and changed its name to Panbela Therapeutics, Inc. in December 2020. Panbela Therapeutics, Inc. was incorporated in 2011 and is based in Waconia, Minnesota.